Publication date: Jul 04, 2024
The COVID-19 pandemic has caused delays in cancer diagnoses and reductions in treatments. The aim of this work is to evaluate the impact of the pandemic on prostate cancer by evaluating whether there has been a shift towards more aggressive (Gleason) and more advanced tumors (stage IV) and a decline in treatments. The study was conducted on 1123 cases of prostate cancer incident in the Province of Reggio Emilia, Northern Italy, in the period of 2018-2021. In 2020, there was a decline in new diagnoses of prostate cancer (-31%), followed by a slight recovery in 2021 (+5%). While Gleason 7 and 8-10 values remained constant, a significant decrease was recorded in stage I (38. 7%, 41. 6%, 35. 5%, and 27. 7%) and an increase in stage IV (13. 1%, 13%, 15. 4%, and 20%) cases in the years 2018, 2019, 2020, and 2021, respectively. However, there was no impact on surgical treatment (which remained constant at around 35%) and radiotherapy (around 39%). Our findings underline the profound impact of COVID-19 on prostate cancer management, highlighting the importance of healthcare resilience in the face of unprecedented disruptions.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Italy | COVID-19 |
| Pandemic | Gleason |
| Prostate | prostate cancer |
| Radiotherapy | radiotherapy |
| stage | |
| surgery |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 Pandemic |
| disease | MESH | Prostate Cancer |
| pathway | KEGG | Prostate cancer |
| disease | VO | population |
| disease | MESH | cancer |
| disease | MESH | emergencies |
| drug | DRUGBANK | Coenzyme M |
| pathway | KEGG | Viral replication |
| disease | MESH | infections |
| disease | MESH | skin cancers |
| disease | MESH | melanomas |
| disease | IDO | quality |
| disease | MESH | death |
| disease | VO | protocol |
| disease | MESH | adenocarcinoma |
| drug | DRUGBANK | Pentaerythritol tetranitrate |
| disease | VO | time |
| disease | VO | USA |
| disease | IDO | intervention |